Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 11Brain Neoplasms 6Gliosarcoma 4Glioma 4Oligodendroglioma 3Astrocytoma 3Thyroid Neoplasms 2Spinal Cord Neoplasms 2Ovarian Neoplasms 2Melanoma 2Medulloblastoma 2Lung Neoplasms 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Soft Tissue Neoplasms 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Pinealoma 1Pharyngeal Neoplasms 1Pancreatic Neoplasms 1Neurofibromatosis 2 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroectodermal Tumors, Primitive 1Neoplasms, Mesothelial 1

Interventions

Cyclophosphamide 10Temozolomide 8Radiotherapy 6Magnetic Resonance Spectroscopy 6Cisplatin 6Filgrastim 5Etoposide 5Carboplatin 5Vincristine 4sargramostim 3Thiotepa 3Melphalan 3Carmustine 3Automobiles 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3fludarabine 2antineoplaston AS 2-1 2antineoplaston A10 2aldesleukin 2Thalidomide 2Paclitaxel 2Irinotecan 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Gadolinium DTPA 2Eflornithine 2Donepezil 2Biopsy 2Bevacizumab 2veliparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive × Disulfides × CNS × Clear all
NCT01217437 2021-07-23

Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

National Cancer Institute (NCI)

Phase 2 Completed
108 enrolled 14 charts
CNS

Medulloblastoma, Pinealoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡